Metabolic
& GLP-1

Metabolic peptide research has been reshaped by the incretin hormones. GLP-1 receptor agonists such as semaglutide and liraglutide, the dual GLP-1/GIP agonist tirzepatide, and triple agonists such as retatrutide that add glucagon-receptor activity are among the most studied peptides in modern endocrinology, with large phase 3 programmes behind several of them.

Newer research compounds widen the field: cagrilintide targets amylin receptors, survodutide and mazdutide combine GLP-1 and glucagon signalling, and fragments such as AOD-9604 have been examined in adipocyte lipolysis models. Researchers use these reference compounds to study appetite signalling, energy expenditure, glucose homeostasis and receptor pharmacology.

Every compound in this category ships lyophilised with a batch-specific certificate of analysis that confirms identity by mass spectrometry and purity by HPLC.